JMJoshua Moller

Joshua Moller

*This is an algorithmically generated author record based on publicly available information.

Joshua Moller has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    2025 Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization

    by Lood van Niekerk, Joshua Moller, Seth Ritter, Porfirio Quintero-Cadena, Rich Cohen, Georgia Channing, Michael Chungyoun, Laura Rand, Alexander Smith, Aanal Bhatt, et al.

    Monoclonal antibodies (mAbs) are among the most successful therapeutic modalities, with over 200 marketed products and nearly 1400 candidates in clinical development.1 While high-affinity binding r...


  • Open Access

    Guided Generation for Developable Antibodies

    by Siqi Zhao, Joshua Moller, Porfi Quintero-Cadena, Lood van Niekerk

    Therapeutic antibodies require not only high-affinity target engagement, but also favorable manufacturability, stability, and safety profiles for clinical effectiveness. These properties are collectively called `developability'. To enable a computational framework for optimizing antibody sequences for favorable developability, we introduce a guided discrete diffusion model trained on natural paired heavy- and light-chain sequences from the Observed Antibody Space (OAS) and quantitative developability measurements for 246 clinical-stage antibodies. To steer generation toward biophysically viable candidates, we integrate a Soft Value-based Decoding in Diffusion (SVDD) Module that biases sampling without compromising naturalness. In unconstrained sampling, our model reproduces global features of both the natural repertoire and approved therapeutics, and under SVDD guidance we achieve significant enrichment in predicted developability scores over unguided baselines. When combined with high-throughput developability assays, this framework enables an iterative, ML-driven pipeline for designing antibodies that satisfy binding and biophysical criteria in tandem.